Dashboard
Manage Tickers

VXRT Vaxart, Inc.

Nasdaq vaxart.com


$ 0.00 (0.66 %)    

CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 605.65 $ 0.00 (0 %)
DIA $ 474.14 $ 0.00 (0 %)
SPY $ 670.63 $ 0.00 (0 %)
TLT $ 89.20 $ 0.00 (0 %)
GLD $ 383.16 $ 0.00 (0 %)
$ 0.365
-- x --
-- x --
-- - --
$ 0.26 - $ 0.98
251,848
na
87.63M
$ 1.36
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-13-2025 09-30-2025 10-Q
2 08-13-2025 06-30-2025 10-Q
3 05-13-2025 03-31-2025 10-Q
4 03-20-2025 12-31-2024 10-K
5 11-13-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-13-2024 03-31-2024 10-Q
8 03-14-2024 12-31-2023 10-K
9 11-02-2023 09-30-2023 10-Q
10 08-03-2023 06-30-2023 10-Q
11 05-04-2023 03-31-2023 10-Q
12 03-15-2023 12-31-2022 10-K
13 11-09-2022 09-30-2022 10-Q
14 08-08-2022 06-30-2022 10-Q
15 05-09-2022 03-31-2022 10-Q
16 02-24-2022 12-31-2021 10-K
17 11-04-2021 09-30-2021 10-Q
18 08-05-2021 06-30-2021 10-Q
19 05-06-2021 03-31-2021 10-Q
20 02-25-2021 12-31-2020 10-K
21 11-12-2020 09-30-2020 10-Q
22 08-06-2020 06-30-2020 10-Q
23 05-12-2020 03-31-2020 10-Q
24 03-19-2020 12-31-2019 10-K
25 11-12-2019 09-30-2019 10-Q
26 08-08-2019 06-30-2019 10-Q
27 05-09-2019 03-31-2019 10-Q
28 02-06-2019 12-31-2018 10-K
29 11-13-2018 09-30-2018 10-Q
30 08-10-2018 06-30-2018 10-Q
31 05-15-2018 03-31-2018 10-Q
32 02-06-2018 12-31-2017 10-Q
33 11-07-2017 09-30-2017 10-Q
34 09-01-2017 06-30-2017 10-K
35 05-08-2017 05-02-2017 10-Q
36 02-06-2017 12-31-2016 10-Q
37 11-08-2016 09-30-2016 10-Q
38 09-13-2016 06-30-2016 10-K
39 05-10-2016 03-31-2016 10-Q
40 02-08-2016 12-31-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

vaxart-otc-vxrt-q3-eps-004-up-from-006-yoy-sales-7241m-up-from-493m-yoy
Vaxart (OTC: VXRT) Q3 EPS $(0.04) Up From ...
11/13/2025 21:07:24

Vaxart (OTC:VXRT) Q3 EPS $(0.04) Up From $(0.06) YoY, Sales $72.41M Up From $4.93M YoY

a-look-at-vaxarts-upcoming-earnings-report
A Look at Vaxart's Upcoming Earnings Report
11/12/2025 19:04:04

Core News & Articles
Dynavax Technologies Collaborates With Vax...
11/05/2025 21:02:58

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing in...

vaxart-withdraws-its-reverse-stock-split-proposal
Vaxart Withdraws Its Reverse Stock Split P...
09/19/2025 12:06:49

Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a rang...

vaxarts-second-generation-oral-norovirus-vaccine-shows-up-to-25-fold-increase-in-protective-fecal-iga-in-phase-1-trial
Vaxart's Second-Generation Oral Norovirus ...
09/10/2025 21:03:32

- Second-generation constructs induce robust increases in fecal IgA, which was shown to be correlated with protection against i...

vaxart-q2-eps-007-beats-009-estimate-sales-39730m-beat-2023m-estimate
Vaxart Q2 EPS $(0.07) Beats $(0.09) Estima...
08/13/2025 20:08:16

Vaxart (NASDAQ:VXRT) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.09) by 19....

vaxarts-earnings-a-preview
Vaxart's Earnings: A Preview
08/12/2025 19:02:15

vaxart-announces-its-common-stock-has-been-approved-to-trade-on-the-otcqx-best-market
Vaxart Announces Its Common Stock Has Been...
07/08/2025 12:10:59

Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a rang...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
07/02/2025 12:06:54

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
07/01/2025 12:07:35

Core News & Articles
12 Health Care Stocks Moving In Friday's I...
06/13/2025 17:06:07

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
06/11/2025 12:07:40

vaxart-reports-topline-results-from-phase-1-clinical-trial-evaluating-second-generation-oral-pill-norovirus-vaccine-constructs-head-to-head-against-its-first-generation-constructs
Vaxart Reports Topline Results From Phase ...
06/11/2025 11:32:12

- Second-generation norovirus constructs produce statistically significant increases in GI.1 and GII.4 norovirus blocking antib...

Core News & Articles
Why Stitch Fix Shares Are Trading Higher B...
06/11/2025 10:23:30

us-stocks-likely-to-open-lower-ahead-of-may-inflation-report-sp-500-still-in-a-31-month-long-bull-market-better-times-are-coming-says-expert
US Stocks Likely To Open Lower Ahead Of Ma...
06/11/2025 09:56:50

vaxart-board-commits-to-high-end-of-1-for-20-reverse-stock-split-ratio
Vaxart Board Commits To High End Of 1-for-...
05/28/2025 19:11:34

-SEC Filing

vaxart-initiates-dosing-in-10000-participant-portion-of-phase-2b-covid-19-trial
Vaxart Initiates Dosing In 10,000-Particip...
05/27/2025 12:01:15

vaxart-receives-barda-approval-to-initiate-dosing-in-10000-participant-portion-of-ongoing-phase-2b-clinical-trial-evaluating-oral-pill-covid-19-vaccine-candidate
Vaxart Receives BARDA Approval To Initiate...
05/15/2025 12:17:00

Vaxart, Inc. (NASDAQ:VXRT) today announced that it has received approval from the Biomedical Advanced Research and Development ...

vaxart-publishes-complete-data-from-phase-2b-challenge-study-of-first-generation-oral-pill-norovirus-vaccine-candidate-in-science-translational-medicine
Vaxart Publishes Complete Data From Phase ...
05/14/2025 20:17:29

Challenge Study measured safety, efficacy against infection and symptomatic disease as well as viral sheddingMachine learning a...

vaxart-appoints-jeroen-grasman-as-cfo-effective-may-19-2025-grasman-succeeds-phillip-lee
Vaxart Appoints Jeroen Grasman As CFO, Eff...
05/13/2025 20:06:41

- Mr. Grasman brings over two decades of biotech financial leadership experience -SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GL...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION